Skip to main content
. 2021 Jul 12;16(7):e0254498. doi: 10.1371/journal.pone.0254498

Fig 4. Protective immunity of viral-vectored P. falciparum antigens.

Fig 4

Protective immunity in mice immunized with ChAd63- and MVA viral-vectored P. falciparum proteins as determined by the (delay in) the day to blood stage patency, i.e. the day to reach 1% parasitemia after challenge with chimeric P. berghei sporozoites expressing the P. falciparum proteins. Eight immunized and eight naïve BALB/c mice and ten immunized and ten naïve CD-1 mice were challenged with 103 chimeric sporozoites by intravenous injection. The Kaplan-Meier curves illustrate the time to 1% parasitaemia and statistical significance between the survival curves was assessed using the Log-Rank (Mantel-Cox) Test (group size of inbred BALB/c mice: n = 6–8; group size of CD-1 outbred mice: n = 9–10. (a) PfHT p = 0.48 (BALB/c) and p = 0.77 (CD-1), (b) PfRPL3 p = 0.43 (BALB/c) and p = 0.86 (CD-1), (c) PfSPELD p = 0.003 (BALB/c) and p = 0.004 (CD1), (d) PfETRAMP10.3 p = 0.14 (BALB/c) and p = 0.38 (CD-1), (e) PfSIAP2 p = 0.48 (BALB/c) and p = 0.20 (CD-1), and (f) PfSPATR p = 0.73 (BALB/c) and p = 0.25 (CD-1).